Table 2 Summary of international and national recommendations for nirservimab prescription
Country | Recommended by | Epidemic season | Recommended in | Administered where | Switch from PVZ to nirsevimab | Included in the immunization calendar |
|---|---|---|---|---|---|---|
USA | CDC, ACIP, AAP | 2023–2024 | 1. All newborns and infants < 8 months born during or entering their first RSV season 2. In newborns and infants with high risk for developing severe RSV infection at their first and second epidemic season (up to 24 months of age) | Hospital inside Hospital outside | Yes | Yes |
France | FHAS | 2023–2024 | All infants under 12 months of age, also including newborns with well-known risk factor for severe RSV infection, at the start of the epidemic season. | Hospital inside Hospital outside | Not stated | Yes |
Spain | Ministerio de Sanidad NITAG | 2023–2024 | 1. All newborns up to 6 months of age at their first RSV season 2. Newborns with risk factors for severe RSV infection at their second RSV season, up to 24 months of age. | Hospital inside Hospital outside | Not stated | Yes |
Italy | Ministry of Health SItI SIMIT SIN SIP FIMP FIMMG | 2024–2025 | All neonates born at their first RSV epidemic season from birth and up to the 13 months of age, also including subjects at high risk for severe RSV infection. | Hospital inside Hospital outside | Not stated | Yes, in the PNPV 2023–2025 |
Germany | STIKO | 2024–2025 | Healthy newborns and infants a risk for developing severe RSV infection born during and outside their first epidemic RSV season. | Hospital inside Hospital outside | Not stated | No |
UK | JCVI | 2023–2024 | Not specified. UK recommended that PVZ was replaced by nirsevimab for the eligible infants. | Hospital inside Hospital outside | Not stated | No |
Luxembourg | SCID | 2023–2024 | 1. All newborns < 6 months at their first RSV season 2. Newborns with risk factors for severe RSV infection at their second RSV season, up to 24 months of age. | Not stated | Not stated | No |
Belgium | SHC | 2023–2024 | 1. All infants younger than 1 year of age entering at the first RSV season 2. All babies born from unvaccinated mothers or born prematurely (< 30 weeks of gestational age) or within the two weeks following the maternal vaccine administration. 3. Infants a risk for developing severe RSV infection at their secondo RSV season, up to 24 months of age. | Hospital inside Hospital outside | Yes | Not stated |
Netherlands | HCN | Â | 1. All children before or during the RSV season, immediately after the birth and within 2 weeks at the latest. 2. Babies born after the RSV season, nirsevimab should be administered before the start of their first RSV season | Not stated | Not stated | Not yet but it is planned |
Sweden | TRR | 2024–2025 | All infants and children at their first season | Not stated | Not stated | No |
Finland | COHERE | 2024–2025 | 1. Healthy newborns and infants younger than 3 months at their first RSV season 2. All children at high risk for severe RSV infection | Not stated | Not stated | No |
Canada | NACI | 2024–2025 | 1. All newborns < 8 months born during or enter their first RSV season and who are at increased risk of severe RSV disease and/or who have complex access to care and are influenced by social determinants | Not stated | Not stated | No |
Brazil | SBIm | 2024–2025 | 1. All newborns during the first RSV season 2. In high-risk newborns during the second season | Not stated | Not stated | No |
Australia | ATAGI | 2024–2025 | All newborns during their first and second RSV season, up to 24 months of age. | Not stated | Not stated | Not stated |
Japan | MHLW | Not stated | To define | Not stated | Not stated | Not yet but it is planned |
Madeira | DRS | 2023–2024 | All newborns during their first RSV season | Not stated | Not stated | Yes |
Chile | CAVEI | March 2024 | 1. All newborns during the first RSV season 2. In high-risk newborns during the second season | Not stated | Not stated | Not stated |